STOCK TITAN

Relief Therapeut - RLFTY STOCK NEWS

Welcome to our dedicated page for Relief Therapeut news (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on Relief Therapeut stock.

Relief Therapeutics (RLFTY) is a biopharmaceutical innovator developing patient-friendly therapies for rare metabolic, dermatological, and respiratory conditions. This page provides authorized updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.

Investors and healthcare professionals will find a comprehensive repository of verified news including trial results, partnership announcements, and financial reports. Key focus areas span proprietary formulation technologies, regulatory submissions, and commercialization efforts for treatments addressing critical unmet medical needs.

Content updates cover essential developments such as clinical study outcomes, FDA/EMA interactions, licensing agreements, and market expansion strategies. All materials are curated to support informed analysis of RLFTY’s progress in advancing therapies like its concentrated PKU formulations and stabilized antimicrobial solutions.

Bookmark this page for streamlined access to Relief Therapeutics’ latest advancements in rare disease research and development. Check regularly for objective updates on pipeline progress and corporate developments shaping the company’s trajectory.

Rhea-AI Summary
RELIEF THERAPEUTICS to present at H.C. Wainwright Global Investment Conference on Sept. 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.45%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.89%
Tags
none
-
Rhea-AI Summary
Relief Therapeutics announces that its state-of-the-art laboratory in Balerna, Switzerland has been audited and approved by Swissmedic, the national authorization and supervisory authority for drugs and medical products. The laboratory meets Good Manufacturing Practice (GMP) standards and offers a comprehensive suite of analytical and development services. The lab is designed to meet forthcoming pharmaceutical challenges and is fully integrated with current R&D capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Relief Therapeutics announces implementation timeline for reverse split of its ordinary shares
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.5%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.66%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics announced positive 12-month stability data for RLF-100 ®, an investigational formulation of aviptadil acetate for inhaled and intravenous administration. Both formulations demonstrated high purity levels after one year across various temperature conditions, confirming previous findings at three and six months. In response to these results, Relief plans to amend its provisional patent application, potentially extending exclusivity until 2042, factoring in possible Hatch-Waxman extensions.

CEO Jack Weinstein emphasized the commercial potential of the stable formulation, aiming to establish RLF-100 ® as a standard treatment for respiratory failure. The FDA previously granted Orphan Drug designation for RLF-100 ® targeting pulmonary sarcoidosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Relief Therapeutics Holdings SA reported its financial results for the full year ending December 31, 2022, highlighting significant advances in its transformation to a commercial-stage biopharmaceutical company. The company secured FDA approval for OLPRUVA™, aimed at treating urea cycle disorders, with a launch anticipated in July 2023. Additionally, the launch of the PKU GOLIKE™ line in the U.S. started in October 2022, with the PKU GOLIKE BAR™ introduced in early 2023. The company also revealed stability data for RLF-100™, enhancing its clinical potential. Relief appointed key leaders for its genetic medicine initiative and is pursuing a dual listing on the Nasdaq. The 2022 annual report is available for download on its website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Relief Therapeutics announced the departure of Dr. Nermeen Varawalla, the Chief Medical Officer, effective Q2 2023. Dr. Varawalla leaves to pursue other opportunities, and the medical affairs team will report to COO Paolo Galfetti until a replacement is found. The company emphasizes that clinical development will be supported by existing consultants. CEO Jack Weinstein praised Varawalla's contributions and reaffirmed the strength of their medical affairs and R&D teams as they focus on advancing their pipeline in metabolic, connective tissue, and pulmonary rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Relief Therapeut

OTC:RLFTY

RLFTY Rankings

RLFTY Stock Data

40.13M
9.56M
Biotechnology
Healthcare
Link
Switzerland
Geneva